Literature DB >> 20518072

Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells.

Thomas De Luca1, Dorothy M Morré, D James Morré.   

Abstract

ENOX2 (tNOX), a tumor-associated cell surface ubiquinol (NADH) oxidase, functions as an alternative terminal oxidase for plasma membrane electron transport. Ubiquitous in all cancer cell lines studied thus far, ENOX2 expression correlates with the abnormal growth and division associated with the malignant phenotype. ENOX2 has been proposed as the cellular target for various quinone site inhibitors that demonstrate anticancer activity such as the green tea constituent epigallocatechin-3-gallate (EGCg) and the isoflavone phenoxodiol (PXD). Here we present a possible mechanism that explains how these substances result in apoptosis in cancer cells by ENOX2-mediated alterations of cytosolic amounts of NAD(+) and NADH. When ENOX2 is inhibited, plasma membrane electron transport is diminished, and cytosolic NADH accumulates. We show in HeLa cells that NADH levels modulate the activities of two pivotal enzymes of sphingolipid metabolism: sphingosine kinase 1 (SK1) and neutral sphingomyelinase (nSMase). Their respective products sphingosine 1-phosphate (S1P) and ceramide (Cer) are key determinants of cell fate. S1P promotes cell survival and Cer promotes apoptosis. Using plasma membranes isolated from cervical adenocarcinoma (HeLa) cells as well as purified proteins of both bacterial and human origin, we demonstrate that NADH inhibits SK1 and stimulates nSMase, while NAD(+) inhibits nSMase and has no effect on SK1. Additionally, intact HeLa cells treated with ENOX2 inhibitors exhibit an increase in Cer and a decrease in S1P. Treatments that stimulate cytosolic NADH production potentiate the antiproliferative effects of ENOX2 inhibitors while those that attenuate NADH production or stimulate plasma membrane electron transport confer a survival advantage. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20518072     DOI: 10.1002/jcb.22724

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  The novel antiangiogenic VJ115 inhibits the NADH oxidase ENOX1 and cytoskeleton-remodeling proteins.

Authors:  Amudhan Venkateswaran; David B Friedman; Alexandra J Walsh; Melissa C Skala; Soumya Sasi; Girish Rachakonda; Peter A Crooks; Michael L Freeman; Konjeti R Sekhar
Journal:  Invest New Drugs       Date:  2012-10-09       Impact factor: 3.850

Review 2.  Sphingosine kinase 1 in cancer.

Authors:  Linda A Heffernan-Stroud; Lina M Obeid
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

3.  Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer.

Authors:  Jan B Howes; Paul L de Souza; Leanne West; Li Jiu Huang; Laurence G Howes
Journal:  BMC Clin Pharmacol       Date:  2011-02-03

4.  Cancer prevention trial of a synergistic mixture of green tea concentrate plus Capsicum (CAPSOL-T) in a random population of subjects ages 40-84.

Authors:  Claudia Hanau; D James Morré; Dorothy M Morré
Journal:  Clin Proteomics       Date:  2014-01-06       Impact factor: 3.988

5.  ENOX2 target for the anticancer isoflavone ME-143.

Authors:  D James Morré; Theodore Korty; Christiaan Meadows; Laura M C Ades; Dorothy M Morré
Journal:  Oncol Res       Date:  2014       Impact factor: 5.574

6.  NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study.

Authors:  Koba Kiknavelidze; Mikheil Shavdia; Nana Chikhladze; Lia Abshilava; Marinella Messina; Gisela Mautner; Graham Kelly
Journal:  Curr Ther Res Clin Exp       Date:  2021-03-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.